Xenon to showcase new long-term azetukalner data at aes 2024

Vancouver, british columbia and boston, nov. 25, 2024 (globe newswire) -- xenon pharmaceuticals inc. (nasdaq: xene), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming american epilepsy society annual meeting (aes 2024), taking place december 6-10, 2024 at the los angeles convention center in los angeles, ca. five posters will be presented, featuring new long-term data from the ongoing x-tole open-label extension study of azetukalner in patients with focal onset seizures (fos), the mental health burden and comorbidity burdens of focal onset seizures, as well as new pre-clinical data from the company's early-stage nav1.1 program.
AES Ratings Summary
AES Quant Ranking